Jannine Versi - May 25, 2023 Form 4 Insider Report for Adamis Pharmaceuticals Corp (ADMP)

Role
Director
Signature
/s/ David C. Benedicto, as Attorney-in-Fact
Stock symbol
ADMP
Transactions as of
May 25, 2023
Transactions value $
$0
Form type
4
Date filed
5/30/2023, 06:14 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMP Common Stock Award +177K 177K May 25, 2023 By Versi Group, LLC F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMP Employee Stock Option (Right to Buy) Award +5.14K 5.14K May 25, 2023 Common Stock 5.14K $2.90 Direct F4
transaction ADMP Employee Stock Option (Right to Buy) Award +5.14K 5.14K May 25, 2023 Common Stock 5.14K $2.90 Direct F4
transaction ADMP Employee Stock Option (Right to Buy) Award +5.14K 5.14K May 25, 2023 Common Stock 5.14K $2.90 Direct F4
transaction ADMP Employee Stock Option (Right to Buy) Award +5.14K 5.14K May 25, 2023 Common Stock 5.14K $2.90 Direct F4
transaction ADMP Employee Stock Option (Right to Buy) Award +5.14K 5.14K May 25, 2023 Common Stock 5.14K $2.90 Direct F4
transaction ADMP Series E Convertible Preferred Stock Award +1.94K 1.94K May 25, 2023 Common Stock 1.94M By Versi Group, LLC F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the trustee of. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interests therein.
F3 Received in exchange for shares of common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.
F4 Received in the Merger by virtue of the assumption of a stock option to acquire shares of DMK common stock in connection with the Merger, with proportionate adjustments to the number of shares subject to the option and the per share exercise price.
F5 Received in the Merger in exchange for shares of common stock of DMK. Each whole share of Series E Preferred Convertible Stock is convertible into 1,000 shares of Adamis common stock at the election of the Reporting Person provided that no portion of the Series E Convertible Preferred Stock may be converted if the Reporting Person or her affiliates own in excess of 9.99% of the number of shares of Adamis common stock outstanding immediately after giving effect of such conversion. On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.